https://www.selleckchem.com/pr....oducts/oxidopamine-h
s, dyslipidemia, chronic renal failure, coronary heart disease, stroke, heart failure and cancer disease was 0.45 (95% CI 0.13-1.5; p = 0.196) for PTS. While HR for the development of PTS adjusted by age, sex, non-steroidal anti-inflammatory drugs, corticosteroids, immobility, anticoagulant treatment, cancer disease and PS of the SU was 0.52 (95% CI 0.17-1.66; p = 0.272). No statistically significant association was found between CE and the development of SPT, although there were a small number of events detected in bot